anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Silica nanoparticles (SiNPs) could induce adverse pulmonary effects, but the mechanism was not clear enough. Metabolomics is a sensitive and high-throughput approach that could investigate the intrinsic causes of adverse health effects caused by SiNPs. The current investigation represented the first in vivo metabolomics study examining the chronic pulmonary toxicity of SiNPs at a low dosage, mimicking real human exposure situation. The recovery process after the cessation of exposure was also taken into consideration. Fisher 344 rats were treated with either saline or SiNPs for 6 months. Half of the animals in each group received an additional six-month period for recovery. The findings indicated that chronic low-level exposure to SiNPs resulted in notable alterations in pulmonary metabolism of amino acids, lipids, carbohydrates, and nucleotides. SiNPs exerted an impact on various metabolites and metabolic pathways which are linked to oxidative stress, inflammation and tumorigenesis. These included but were not limited to L-carnitine, spermidine, taurine, xanthine, and glutathione metabolism. The metabolic alterations caused by SiNPs exhibited a degree of reversibility. However, the interference of SiNPs on two metabolic pathways related to tumorigenesis was observed to persist after a recovery period. The two metabolic pathways are glycerophospholipid metabolism as well as phenylalanine, tyrosine and tryptophan biosynthesis. This study elucidated the metabolic alterations induced by chronic low-level exposure to SiNPs and presented novel evidence of the chronic pulmonary toxicity and carcinogenicity of SiNPs, from a metabolomic perspective.
The present invention provides adjuvants, for use in vaccine formulation, comprising a water-in-oil emulsion, characterised in that said emulsion comprises a polymeric emulsifier which is a block copolymer having a general formula A-COO-B-OOC-A, in which B is the divalent residue of a water-soluble polyalkylene glycol and A is the residue of a oil-soluble complex monocarboxylic acid. Such polymeric emulsifier, as well as the preparation thereof, has been disclosed in GB 2002400 and WO9607689. Preferably in the blockcopolymers of formula A-COO-B-OOC-A, component B is derived from polyethylene glycol and components A are derived from polyhydroxystearic acid, preferably from poly(12-hydroxy-stearic acid). Most preferred emulsifiers used in the adjuvants according to the invention are Arlacel P135, a PEG 30 Dipolyhydroxystearate. Another, similar, emulsifier for use with the invention is ATLOX®4912. Both Arlacel P135 and ATLOX®4912 are block copolymers (A-B-A) of polyethylene glycol and hydroxystearic acid with a molweight of approximately 5000 commercially available from ICI. It has een found that with the use of these emulsifiers adjuvants based on w/o emulsions that are stable and have a low viscosity can be obtained that may be based on metabolisable oils. Said adjuvants have an excellent adjuvant activity, and are well tolerated.
A cosmetic composition containing the extract of Phaseolus radiatus L. var. aurea Prain flower or leaf is provided to improve skin beauty by extracting the Phaseolus radiatus L. var. aurea Prain flower or leaf having whitening and anti-aging effects in polar solvent to low polar solvent, successively to increase the amount of the effective ingredients and maximize stability. A cosmetic composition contains 0.0001-10 wt.% of the extract of Phaseolus radiatus L. var. aurea Prain flower or leaf which is prepared by pulverizing Phaseolus radiatus L. var. aurea Prain flower or leaf, extracting the pulverized product with C1-C4 anhydrous or hydrous lower alcohol including ethanol and methanol, a mixture of water and lower alcohol, acetone, 1,3-butylene glycol, n-propanol, iso-propanol or n-butanol, filtering and concentrating the solvent extract under reduced pressure, extracting the concentrated extract with ethyl acetate or methylene chloride, treating the extract with active charcoal, and concentrating the active charcoal treated extract in a distiller with a cooling condenser under reduced pressure.
Twenty patients were treated with SMA in two steps. They were randomly assigned to one of two groups (n=10): SPG (small particles group) and LPG (large particles group). Different size ABBM particles were implanted in their maxillary sinus, accordingly. A vertical bone core biopsy was obtained at the implant site using a punch trephine. The samples were processed for histological observation and measured histomorphometrically to determine the percentage onewly formed bone (%NB), bone substitute (%BS), bone marrow (%BM), and osseointegration (%OI). Results were statistically analyzed using Student's t test (p ≤ 0.05).
Active Comparator (Group B) will receive transverse abdominas strength training. Treatment will be given 5 days a week and continued for 6 weeks.
Eligible subjects will be randomized to the CONTROL lens to wear in both eyes for approximately 2 weeks. Then the subject will receive the TEST lens to wear in both eyes for approximately 2 weeks.
The present invention relates to novel therapeutic ways for treating Wolfram Syndrome (WS) by targeting the neuronal calcium sensor 1 (NCS1). The present inventors have demonstrated that WFS1, which loss of function is responsible of the Wolfram Syndrome, forms a complex with the neuronal calcium sensor 1 (NCS1). The inventors have further demonstrated that WFS1 associates with NCS1 to prevent its degradation by the proteasome and that NCS1 regulates VDAC expression and mitochondrial respiratory chain. Thus, present invention provides an agonist of NCS1 for use in the treatment of WS. Such an agonist is e.g. a NCS1-encoding polynucleotide, an inhibitor of the proteasome or of calpains. The inventors have further shown that overexpression of NCS1 in WS cells allows increasing complex II driven respiration. The present invention further relates to a method for predicting the severity of WS by measuring the NCS1 level in a sample obtained from a patient.
Participants will be counseled to follow physical activity recommendations for Canadians, which is at least 150 minutes of moderate physical activity per week. Participants will be asked to participate in aerobic, strength training and stretching activities. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their physical activity goals. More participants will be randomized to this group and the participants will either have CDE or a Registered Kinesiologist (R. Kin) as their health coach.
The study consists of 3 phases: Screening Phase (within 21 days prior to randomization), Treatment Phase (Cycle 1 Day 1 to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, withdrawal of consent, or the study ends, whichever occurs first). Treatment phase will include 2 treatments (Treatment A: participants will receive Velcade MelphalanPrednisone (VMP) alone and Treatment B: participants will receive daratumumab in combination with VMP).Two interim analyses are planned. The first will be to evaluate safety after a total of approximately 100 participants have been treated for at least 2 cycles or discontinued the study treatment. The second will be to evaluate cumulative interim safety and efficacy data, and will be performed when approximately 216 PFS events have been accumulated. The final OS analysis will occur when approximately 382 deaths have occurred. Efficacy will be primarily measured by comparison of PFS between the two treatment arms. Participants' safety will be monitored throughout the study.
Using one hand, place the thumb on the acromioclavicular joint in the natural recess or "pocket" between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
Air pollution has been recognized as a contributing factor to sleep disorders (SD), which have been correlated with an elevated susceptibility to a variety of human diseases. Nevertheless, research has not definitively established a connection between SD and interior decorative volatile organic compounds (ID-VOCs), a significant indoor air pollutant. In this study, we employed a mouse model exposed to ID-VOCs to explore the impacts of ID-VOCs exposure on sleep patterns and the potential underlying mechanism. Of the 23 key compositions of ID-VOCs identified, aromatic hydrocarbons were found to be the most prevalent. Exposure to ID-VOCs in mice resulted in SD, characterized by prolonged wake fullness and decreased sleep during the light period. ID-VOCs exposure triggered neuroinflammatory responses in the suprachiasmatic nucleus (SCN), with microglia activation leading to the overproduction of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1α (IL-1α), and complement component 1q (C1q), ultimately inducing A1 astrocytes. Consequently, the upregulation of branched chain amino acid transaminase 2 (BCAT2) in A1 astrocytes resulted in elevated extracellular glutamate and disruption of the wake-sleep transition mechanism, which might be the toxicological mechanism of SD caused by ID-VOCs.
<P>PROBLEM TO BE SOLVED: To create a composition which compensates for the defects that a dietary fiber and a rare sugar each have and has a new improvement of the biological function as well.  <P>SOLUTION: The biological function improving composition includes a dietary fiber and a rare sugar as active ingredients. The biological function improving composition includes the dietary fiber in an amount of not less than 1 wt.% based on the entire composition and the rare sugar and/or its derivative in an amount of not less than 2 wt.% based on the entire composition. The rare sugar is D-psicose and/or its derivative. The improvement of the biological function is one or more improvements of liver function, a blood sugar level, a serum lipids value, an increase in weight, and visceral fat accumulation. The dietary fiber is a water soluble dietary fiber. The dietary fiber is a scarcely-digestible dextrin. Food and drink, a health food, a drug, a quasi drug, an oral composition or a cosmetic includes the above biological function improving composition. A method for producing food and drink, a health food, a drug, a quasi drug, an oral composition or a cosmetic includes incorporating the above biological function improving composition.  <P>COPYRIGHT: (C)2010,JPO&INPIT
FIELD: food industry. SUBSTANCE: intestine function-controlling biologically active food additive is prepared in the form of fruit plates consisting of plasticized substrate with, imbedded therein, monoglycerides, milled plant ingredients (in particular, senna leaves), and also flavoring and aromatizing substances. The substrate consists of natural honey supplemented with milled dried apricots, flax seeds, laminaria thallus, plantain leaves, dill fruits, citric acid, microcrystalline cellulose at proper ingredient proportion. Additive is prepared by milling and introducing plant and process ingredients into liquid substrate, cooking, stirring, and boiling away intermediate product in mixer, cooling and molding resulting paste into plates. EFFECT: improved organoleptic and curing properties. 2 cl
The aim of this study was to investigate whether the polymorphisms of the ADAMTS7 gene affect the risk of occurrence and mortality due to CAD. The study group included 231 patients diagnosed with CAD and 240 control blood donors. The genotyping of specified polymorphisms, i.e., rs1994016, rs3825807, and rs7173743, was performed using the TaqMan-PCR. We found that the C allele carriers of the rs1994016 and A allele carriers of the rs3825807 polymorphisms increased the risk of CAD, respectively: OR = 1.72, p = 0.036; OR = 1.64, p = 0.04. Moreover, we studied the biological interactions of specified variants, i.e., rs3825807, rs1994016, and rs7173743, and previously approved risk factors of CAD. We demonstrated here that selected polymorphisms of ADAMTS7 increased the risk of CAD altogether with abnormalities of total cholesterol and LDL concentrations in serum. Although survival analyses did not reveal statistical significance, we observed a trend for the AA genotype of the rs3825807 ADAMTS7, which may predispose to death due to CAD in a 5-year follow-up. In conclusion, the ADAMTS7 polymorphisms investigated in this study may increase the risk of occurrence and/or death due to CAD in the Polish population.
The polypill intervention will be pharmacy-level over-encapsulation of heart failure medications (beta-blocker, SGLT2 inhibitor, mineralocorticoid receptor antagonist, and ACE/ARB/ARNI) into a single capsule. For patients on twice-daily sacubitril/valsartan, one dose will be included in the polypill and the second dose will be dispensed separately. The investigators will partner with a local community pharmacy with proficiency in over-encapsulation. For patients in the polypill arm, heart failure medications will be filled as usual, but rather than dispensing each medication separately, the pharmacy technician will hand-pack all once-daily heart failure medications into a small vegan capsule.
At Fraunhofer ITEM, a novel technique to create an atmosphere loaded with allergenic particles was recently developed. In brief, particles are produced in a combined process of nebulization and drying of a solution containing soluble allergenic extracts and lactose. The particle size distribution is regulated by the droplet size distribution and the lactose concentration in the solution, while the allergen content can be chosen independently. Thus, the Fraunhofer scientists have created a universal tool which provides them with the possibility to create atmospheres containing allergenic particles of arbitrary sizes containing a variety of different allergens. By choosing particle sizes preferentially depositing in the nose (above 10 µm) or the lungs (5 to 10 µm), and selecting allergen concentrations commonly found in the environment, it is possible to build up challenge atmospheres for a large variety of indications.

The first clinical application of this new method will be to create an atmosphere simulating the natural exposure to house dust mite allergens. The challenge aerosol will be composed of lactose as carrier material and the two major allergens Der p1 and Der p2 of house dust mites originating from a licenced allergen extract for inhaled challenge.
The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
The present invention provides a solid shampoo, including the following components in percentage by weight: sodium cocoyl isethionate 50-80%, first surfactant 1-10%, second surfactant 0.5-20%, polyhydric alcohol humectant 1-20% and preservative 0.1-2%; The first surfactant comprises one or two of the following: sodium lauryl sulfoacetate and disodium laureth sulfosuccinate. The second surfactant comprises one or more of the following: coco-glucoside, cocamidopropyl betaine and disodium lauroamphodiacetate. The solid shampoo is in the form of solid structure. The solid shampoo is gentle and non-irritating. The solid shampoo is free of irritating ingredients such as silicon oil. Recyclable or biodegradable paper packaging can be used preferably to reduce energy consumption. The present invention also provides a method for preparing the solid shampoo.
Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Osimertinib 80mg p.o, qd. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
Epidemiologic studies have shown that cerebrovascular accident (CVA) is the 3rd cause of death in developed countries with 0.8 % prevalence in the whole population. Although, the prevalence rate of stroke is reduced yet is one of the most important health problems in the United State. Periodontitis and gingivitis are the two most infectious man diseases. Today, it is estimated that about 35% of people over 30-year-old in America and 50-55% of people in developing countries are involved with these diseases.

These diseases are due to the practice of chronic bacterial infection and the inflammatory response of the host. The relationship between periodontitis and CVA was first introduced by Mackenzi and Millard in 1963 but the importance of this issue was not understood. Periodontal infection can be a complex multiphase disease by associating this infection with organ systems such as cardiovascular, endocrine, reproductive, and respiratory systems. Nowadays, periodontitis is considered a risk factor for atherosclerosis and thromboembolic disease.
NEW MATERIAL:A compound expressed by formula I [R1 and R2 are H, OH or halogen; R3 and R4 are carbamoyl or carboxyl which may be protected; A is formula II-IV (X and Y are OH which may be protected substituted OH, etc.; Z is H or OH which may be protected; W, together with N, forms N-oxide, lower alkyloxy, etc.] and salt thereof. EXAMPLE:Griseolic acid-N<1>-oxide dimethyl ester. USE:A cardiovascular agent, antithrombotic agent, ameliorant for cerebral function, diuretic agent, agent for cranial nerves, smooth muscle relaxant and remedy for cancer. PREPARATION:Dimethyl griseolate expressed by formula V is suspended in methanol, and m-chloroperbenzoic acid is added and reacted therewith at room temperature to afford the aimed compound (exemplified compound) expressed by formula I (R1 and R2 are OH; R3 and R4 are carboxy protected with methyl; A is formula IV (W is N-oxide).
LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
150,319. Elektro-Osmose Akt.-Ges., (Graf Schwerin Ges.). Aug. 19, 1919, [Convention date]. Addition to 150,318. Vaccines.-The process described in the parent Specification for killing bacteria by. means of a current of electricity is applied to the treatment of pure cultures oL various micro-organisms for the preparation of specific vaccines. By treatment for a shorter period or with a smaller current the organisms are not killed, but become non-pathogenic, and may be used directly for the preparation of vaccines or for the preparation of sub-cultures on artificial nutrients. These subcultures are also non-pathogenic and may be used for making vaccines containing the living bacteria. Bacteria to be treated are separated from their culture medium, emulsified in physiological salt solution by continued shaking, and treated by the electric current. Data are given for the treatment of swine erysipelas bacilli, pueumococci, and tubercle bacilli. Known processes for the preparation of vaccines by treating bacteria at a temperature of 56-60‹ C. or by means of disinfectants such as cresol and phenol are referred to.
A system and a method for managing payments for accessing patients' information are disclosed. The method includes receiving a request from a third party user. The request corresponds to accessing the patients information stored in a blockchain database. The method further includes determining at least one type of the patients' information requested by the third party user. Further, the method includes receiving an authorization from the patient to provide an access of the patients information to the third party user. Thereafter, a payment is calculated based at least on the at least one type of the patients information and the authorization. Finally, access may be provided to the patients information upon receiving the payment.
OBJECTIVES: In cardiovascular disease, previous studies have suggested young age as one of the reasons to explain the obesity paradox. This study attempts to provide a different opinion on this claim through unexpected findings.
METHODS: We used a cross-sectional analysis of the US nationally representative data, total of 10,175 participants were recruited in 2013-2014 from NHANES. A total of 947 participants were selected to be included in this study through inclusion criteria and exclusion criteria for statistical analysis of the relationship between obesity and abdominal aortic calcification(AAC). Smooth curve fitting and multivariate regression analyses were conducted to examine the associations of obesity with AAC after adjusting for age, gender and associated variates.
RESULTS: Depending on the age of the population, the relationship between obesity and AAC showed the different outcome. Obesity was associated with the lower risk of AAC among individuals older than 52 years of age. According to the difference of adjusted covariates, the AAC scores in the obesity group decreased by 0.92, 0.87, and 1.11 for 52 years old or older individuals. In particular, the risk of AAC was lower for patients with obesity with the following characteristics: male, low LDL, low triglyceride, DM, non-cancer patient, smoking, drinking, vigorous work activity, low annual household income, education of 9 - 11th grades and non-Hispanic white.
CONCLUSIONS: In US, adults aged 52 years or older, obesity was associated with decreased AAC risk. Older age may be one potential reason for the obesity paradox.
In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
Participants will be administered the matching placebo sublingual film following start of an autonomic crisis. In case the crisis has not subsided after 2 hours, the patient will be instructed to take the second dose. The maximum amount for the study is two oral films within two hours for each episode but not more than 24 hours apart, one at the beginning of the crisis and if needed, one additional within two hours.
The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
The epidural space will be identified in the seated position between the L2 and L5 interspaces with a 17G-10 cm Tuohy epidural needle (CHS ®, Oakville, ON, Canada) using a loss of resistance to saline technique. In both groups, a needle-through-needle technique will be performed using a 25G 5-inch Whitacre spinal needle (BD®, Franklin Lakes, NJ, USA).In Group EPL, no dural puncture will be performed and the catheter will be threaded 4-5cm in the epidural space.